hCD3EDG/hCD19/hBCMA
Nomenclature
C57BL/6JSmo-Tnfrsf17tm1(hBCMA)Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Cd19tm1(hCD19)Smoc
Cat. NO.
NM-XA-242443
Strain State
Repository Live
Model Description
Validation Data
Fig.1 Expression analysis of hBCMA in spleen of hCD3EDG/hCD19/hBCMA humanized mice.
Leukocytes were collected from homozygous hCD3EDG/hCD19/hBCMA mice that had been treated with or without GSI (γ-secretase inhibitor) in vivo, and analyzed by flow cytometry with anti-hBCMA. hBCMA was exclusively detectable in hBCMA humanized mice but not in wild-type mice.
Fig.2 Expression analysis of hBCMA in spleen of hCD3EDG/hCD19/hBCMA humanized mice.
Leukocytes were collected from homozygous hCD3EDG/hCD19/hBCMA mice, treated with or without 1 μM GSI (γ-secretase inhibitor) in vitro, and analyzed by flow cytometry with anti-hBCMA. hBCMA was exclusively detectable in hBCMA humanized mice but not in wild-type mice.
Fig.3 Detection of immune cell subpopulations in the blood of 7-8-week-old female mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.
Fig.4 Detection of immune cell subpopulations in the blood of 7-8-week-old male mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.
Fig.5 Detection of immune cell subpopulations in the spleen of 7-8-week-old female mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.
Fig.6 Detection of immune cell subpopulations in the spleen of 7-8-week-old male mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.
Fig.7 Detection of immune cell subpopulations in the lymph nodes of 7-8-week-old female mice by FACS (n=2 or 3).
Abbr. WT, wild type; HO, homozygous.
Fig.8 Detection of immune cell subpopulations in the lymph nodes of 7-8-week-old male mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.
Table 1. Blood routine examination of hBCMA/hCD3EDG/hCD19 knockin mice. The baseline physiological parameters of hCD3EDG/hCD19/hBCMA mice showed no significant abnormalities.
Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SEM.
Table 2. Biochemical test of serum from hBCMA/hCD3EDG/hCD19 knockin mice.
Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SEM.
Fig.9 In vivo efficacy study of teclistamab in HO hCD3EDG/hCD19/hBCMA mice. Teclistamab were injected at day 0, 3, 5, and immune cells in the spleen and bone marrow of mice after therapy were measured by flow cytometry (n=4).
Teclistamab treatment resulted in a significant reduction of plasma cells in both the spleen and bone marrow of hCD3EDG/hCD19/hBCMA mice. Average±SEM.
Fig.10 Detection of BCMA expression in serum of hTROP2 mice by ELISA.
Fig11. Homozygous hCD3EDG/hCD19/hBCMA mice express human CD3 on TACI+ CD138+ plasma cells.
Fig12. Homozygous hCD3EDG/hCD19/hBCMA mice express human CD19 on TACI+ CD138+ plasma cells.
Fig13. Homozygous hCD3EDG/hCD19/hBCMA mice express human BCMA on TACI+ CD138+ plasma cells.
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
